|
Jul 2
|
Hologic Faces Molecular Drag, But Here's Why It's Not a Major Concern
|
|
Jun 30
|
Changes to the Roche Enlarged Corporate Executive Committee
|
|
Jun 27
|
Initiation of commercialization of ProNephro AKI (NGAL) for diagnostic use in the US
|
|
Jun 26
|
Will MRK's Growing Pipeline Help Navigate the Looming Keytruda LOE?
|
|
Jun 26
|
Innovation in Focus: Highlights from the Two-Day London Biotechnology Show 2025
|
|
Jun 20
|
Genentech’s Lunsumio and Polivy Combination Significantly Prolongs Remission for People With Relapsed or Refractory Large B-cell Lymphoma
|
|
Jun 20
|
Roche’s Lunsumio and Polivy combination significantly prolongs remission for people with relapsed or refractory large B-cell lymphoma
|
|
Jun 19
|
MAIA Biotechnology, Roche sign supply agreement for cancer therapies
|
|
Jun 17
|
Roche’s Phase 3 Move Boosts Outlook for Prothena Corporation plc (PRTA)
|
|
Jun 17
|
AbbVie's Venclexta Misses Goal in Myelodysplastic Syndromes Study
|
|
Jun 16
|
Genentech Provides Update on Phase III Verona Study
|
|
Jun 16
|
Genentech to Advance Prasinezumab Into Phase III Development for Early-Stage Parkinson’s Disease
|
|
Jun 16
|
Roche to advance prasinezumab into Phase III development for early-stage Parkinson's disease
|
|
May 24
|
Tandem Diabetes, Roche enter patent settlement agreement
|
|
May 23
|
CHMP recommends EU approval of Roche’s Itovebi for PIK3CA-mutated, ER-positive, HER2-negative, advanced breast cancer
|
|
May 23
|
Roche announces new collaboration with Broad Clinical Labs to accelerate adoption of cutting-edge SBX sequencing technology
|
|
May 23
|
New Two-year Follow-up of Genentech’s Columvi Extends Overall Survival in Relapsed or Refractory Diffuse Large B-cell Lymphoma Patients
|
|
May 23
|
New two-year follow-up of Roche’s Columvi extends overall survival in relapsed or refractory diffuse large B-cell lymphoma patients
|
|
May 22
|
FDA approves Roche’s Susvimo for diabetic retinopathy
|
|
May 22
|
FDA Approves Genentech’s Susvimo for Diabetic Retinopathy
|